Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
09:03am, Sunday, 17'th May 2026
Gilead Sciences NASDAQ: GILD Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammat
Gilead Prices $3 Billion of Senior Unsecured Notes
09:21pm, Thursday, 14'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, tod
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
10:30am, Wednesday, 13'th May 2026
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Gilead's Transition Into A Long-Duration Biotech Platform
09:15am, Wednesday, 13'th May 2026
Gilead Sciences is executing a successful transition from a mature antiviral company to a diversified therapeutic platform, driving a 34% stock rally. HIV revenue grew 10% YoY, with Yeztugo's explosiv
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
08:30am, Wednesday, 13'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of t
Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
08:00pm, Tuesday, 12'th May 2026
Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View
12:26pm, Friday, 08'th May 2026
GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
01:01am, Friday, 08'th May 2026
Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:01pm, Thursday, 07'th May 2026
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e
Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
06:16pm, Thursday, 07'th May 2026
Gilead Sciences (GILD) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.81 per share a year ago.
Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
04:39pm, Thursday, 07'th May 2026
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
04:05pm, Thursday, 07'th May 2026
Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for the year due to charges and financing cos
Gilead Sciences Announces First Quarter Financial Results
04:01pm, Thursday, 07'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another stro
Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF
02:40pm, Tuesday, 05'th May 2026
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--Gilead's Earnings per Share Expected to Be Up 52% as Florida's and other States' AIDS Drug Programs Falters, says AHF.
Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
06:01am, Tuesday, 05'th May 2026
Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but U.S. health providers say not all patients are interested in the new option a
